These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 8129746

  • 1. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines.
    Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF, Hamilton TC.
    Biochem Pharmacol; 1994 Feb 11; 47(4):689-97. PubMed ID: 8129746
    [Abstract] [Full Text] [Related]

  • 2. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
    Johnson SW, Swiggard PA, Handel LM, Brennan JM, Godwin AK, Ozols RF, Hamilton TC.
    Cancer Res; 1994 Nov 15; 54(22):5911-6. PubMed ID: 7954422
    [Abstract] [Full Text] [Related]

  • 3. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
    Shellard SA, Hosking LK, Hill BT.
    Cancer Res; 1991 Sep 01; 51(17):4557-64. PubMed ID: 1873800
    [Abstract] [Full Text] [Related]

  • 4. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines.
    Zhen W, Link CJ, O'Connor PM, Reed E, Parker R, Howell SB, Bohr VA.
    Mol Cell Biol; 1992 Sep 01; 12(9):3689-98. PubMed ID: 1380646
    [Abstract] [Full Text] [Related]

  • 5. Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines.
    Johnson SW, Shen D, Pastan I, Gottesman MM, Hamilton TC.
    Exp Cell Res; 1996 Jul 10; 226(1):133-9. PubMed ID: 8660948
    [Abstract] [Full Text] [Related]

  • 6. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
    McKeage MJ, Abel G, Kelland LR, Harrap KR.
    Br J Cancer; 1994 Jan 10; 69(1):1-7. PubMed ID: 8286188
    [Abstract] [Full Text] [Related]

  • 7. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells.
    Materna V, Liedert B, Thomale J, Lage H.
    Int J Cancer; 2005 Jun 20; 115(3):393-402. PubMed ID: 15688364
    [Abstract] [Full Text] [Related]

  • 8. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W, Chaney SG.
    Cancer Res; 1993 Feb 15; 53(4):799-805. PubMed ID: 8428361
    [Abstract] [Full Text] [Related]

  • 9. Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation.
    Hill BT, Shellard SA, Hosking LK, Fichtinger-Schepman AM, Bedford P.
    Int J Radiat Oncol Biol Phys; 1990 Jul 15; 19(1):75-83. PubMed ID: 2380098
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.
    Parker RJ, Vionnet JA, Bostick-Bruton F, Reed E.
    Cancer Res; 1993 Jan 15; 53(2):242-7. PubMed ID: 8417816
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Characterisation of the unusual expression of cross resistance to cisplatin in a series of etoposide-selected resistant sublines of the SuSa testicular teratoma cell line.
    Shellard SA, Hosking LK, Hill BT.
    Biochem Pharmacol; 1994 Mar 02; 47(5):775-9. PubMed ID: 8135853
    [Abstract] [Full Text] [Related]

  • 14. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
    Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA, Harrap KR.
    Cancer Res; 1992 Jul 15; 52(14):3857-64. PubMed ID: 1617660
    [Abstract] [Full Text] [Related]

  • 15. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L.
    Cancer Chemother Pharmacol; 2001 Nov 15; 48(5):398-406. PubMed ID: 11761458
    [Abstract] [Full Text] [Related]

  • 16. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin.
    Liedert B, Materna V, Schadendorf D, Thomale J, Lage H.
    J Invest Dermatol; 2003 Jul 15; 121(1):172-6. PubMed ID: 12839578
    [Abstract] [Full Text] [Related]

  • 17. Lack of significant modulation of the formation and removal of platinum-DNA adducts by aphidicolin glycinate in two logarithmically-growing ovarian tumour cell lines in vitro.
    Dempke WC, Shellard SA, Fichtinger-Schepman AM, Hill BT.
    Carcinogenesis; 1991 Mar 15; 12(3):525-8. PubMed ID: 1901253
    [Abstract] [Full Text] [Related]

  • 18. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.
    Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC.
    Cancer Res; 1997 Mar 01; 57(5):850-6. PubMed ID: 9041185
    [Abstract] [Full Text] [Related]

  • 19. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
    Peters GJ, Van Moorsel CJ, Lakerveld B, Smid K, Noordhuis P, Comijn EC, Weaver D, Willey JC, Voorn D, Van der Vijgh WJ, Pinedo HM.
    Int J Oncol; 2006 Jan 01; 28(1):237-44. PubMed ID: 16328001
    [Abstract] [Full Text] [Related]

  • 20. Synthesis of trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its activity in human ovarian tumour models.
    Deqnah N, Yu JQ, Beale P, Fisher K, Huq F.
    Anticancer Res; 2012 Jan 01; 32(1):135-40. PubMed ID: 22213298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.